News and Events for Glycomine
August 30, 2023
Data from Glycomine’s Ongoing Natural History Study Provides Insight into Clinical Measures and Biomarkers for PMM2-CDG
January 9, 2023
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
July 11, 2022
Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors
December 17, 2021
Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
June 29, 2021
Glycomine’s Natural History Study Informs Potentially Lifesaving Update To Standard Of Care For PMM2-CDG Patients
June 23, 2021
Glycomine Closes $68 Million Series B To Advance Into Clinical Trials A Novel Treatment For PMM2-CDG, A Rare Glycosylation Disease
August 1, 2019
Glycomine, Inc. Announces $33 Million Series B Financing To Advance Its Therapy For A Congenital Disease Of Glycosylation
November 16, 2016